Park Medi World operates a chain of 17 multi-super specialty hospitals across North India, delivering affordable tertiary care largely to government insurance scheme patients. As of June 2026, it runs 3,960 beds, with high-end specialties (cardiology, oncology, neurology, joint replacement, urology, gastroenterology) contributing roughly 62% of revenue, up 440 basis points year on year. The payer mix is 77% government schemes, which the company plans to shift to a 70:30 government-to-private split within 12-18 months. Its Q1 FY27 EBITDA margin came in at 26.5% and PAT margin at 18.6%, with FY26 full-year EBITDA margin at 26% and PAT margin at 16%. The company is the largest private hospital chain in Haryana and the Tri-City area and the second-largest in North India, while its capex per bed of about Rs.36-37 lakh is materially lower than listed peers, a cost advantage that underpins its positioning in the affordable segment.
The economics persist because the cost and execution advantages are not easily replicable. Park Medi World builds in-house, has deep vendor relationships that allow payments within 10-15 days, and operates a full-time doctor model where clinicians are not pressured on revenue or volume, kept instead on patient satisfaction and clinical outcomes. This keeps attrition low and allows cluster hospitals within a 50-km radius to share high-end capabilities like robotics and transplants. Its acquisition playbook targets distressed assets at deep discounts; 10 of its 16 hospitals were acquired, with weighted average EBITDA break-even of 3-3.5 years and revenue recovery typically within 11 months. Government claim disallowance is maintained at just 8-9%, reflecting strong clinical documentation, and all hospitals are NABH accredited with NABL labs expanding. No competitor has yet replicated this scale at a similar cost structure, making the niche defensible.
The inflection is the commissioning of roughly 1,500-2,000 new beds over the next 18-24 months. In calendar 2026, the company is adding 1,490 beds (a 46% increase over CY25), with 450 beds coming online in November-December 2026: the 100-bed Palam Vihar extension, the 150-bed Zirakpur acquisition (for about Rs.107 crore), and the 200-bed Narela hospital acquired under IBC. By March 2027, capacity reaches 4,740 beds, and by March 2028 it reaches 5,740, up from 3,960. Management guides FY27 revenue of Rs.2,080 crore (+24% year on year), EBITDA of Rs.530 crore, and PAT of Rs.360 crore, with new units like Agra (360 beds, commissioned February 2026) expected to add Rs.90 crore revenue and become EBITDA positive in FY27. The 350-bed Panchkula Greenfield, commissioned April 10, 2026, should break even in 12-15 months, while the 330-bed Rudrapur acquisition (Rs.177 crore) is targeted to deliver Rs.100 crore in year one. Occupancy is currently 56% due to the heavy capacity addition, but as these units ramp, revenue and operating leverage should build through FY27 and FY28.
Management walk-talk shows consistent delivery against its own targets. The bed capacity goal for March 2028 has been raised twice, from 5,260 to 5,460 and then to 5,740, and the company has met its commissioning dates so far: Agra commenced in February 2026, Panchkula in April 2026, and Rudrapur in August 2026, with Narela on track for Q2 FY27. FY26 EBITDA margin of 26% matched the prior guidance, while PAT margin of 16% was one point below the earlier 17% target but still up 83 basis points year on year. Debt reduction has been dramatic, from Rs.450 crore gross term debt in FY25 to Rs.28 crore at March 2026, and the company plans to repay that remaining debt in Q1 FY27. Capex for FY27-FY28 is budgeted at Rs.767 crore for 2,130 additional beds, fully funded through internal accruals and IPO proceeds, with no material fresh debt. The guidance upgrades and on-time execution give confidence that the capacity additions are real rather than aspirational.
The earnings path is clear: with FY27 revenue at Rs.2,080 crore and 5,740 beds by March 2028, the 18-24 month picture points to revenue around Rs.2,500-2,600 crore, EBITDA near Rs.650-680 crore (at 26% margin), and PAT around Rs.440-460 crore. For that to hold, new hospitals must lift occupancy from the current 56% toward 60-65%, the payer mix must shift to 70:30, and the CGHS rate hike (12-15% across line items, net benefit 5-6% in FY27) must flow through without being fully reinvested in capex. The key falsifier is occupancy: if the recently commissioned units fail to ramp and network occupancy stays below 60%, operating leverage will not materialize and margins could compress despite stable unit economics. A further risk is policy-driven disallowances on government receivables, though the current 9% rate is already low. The tension between falling occupancy and rising PAT margin is operational, not structural; the j-curve remains intact as long as the ramp-up schedules are met.
companyname: PARKHOSPS ticker: PARKHOSPS sector: Not classified Park Medi World Limited, listed as PARKHOSPS, operates a network of multi-super specialty hospitals across North India, with a focus on providing high-quality tertiary and quaternary care at price points accessible to the mass market. As of June 30, 2026, the company operated 3,960 beds across 16 hospitals, having added 960 beds in the preceding 12 months through new facilities in Bathinda (250 beds), Agra (360 beds), and Panchkula...
Read the full report →capex, margin expansion, geographic expansion, order book surge
FY28 bed capacity guided at 5,460 driven by 1,500 beds under execution
Guidance upgradedGet valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Park Medi World Ltd and 4,900+ companies.
5-day free pass. No card required.